Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Plasma or Serum: Which Is Preferable for Mutation Detection in Liquid Biopsy?

Clinical chemistry - 1 Jul 2020

Pittella-Silva Fabio, Chin Yoon Ming, Chan Hiu Ting, Nagayama Satoshi, Miyauchi Eisaku, Low Siew-Kee, Nakamura Yusuke

Abstract excerpt

BACKGROUND: Blood-based analysis of circulating tumor DNA (ctDNA) is a promising tool for cancer screening, monitoring relapse/recurrence and evaluating response to treatment. Although plasma is widely used to obtain ctDNA, biorepositories worldwide possess a huge number of serum samples and comparative studies on the use of serum vs plasma as ctDNA sources are essential. METHODS: We analyzed cell-free DNA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Circulating Tumor DNA
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Copy Number Variations

Share to DNA Fragmentation

Share to Gene Rearrangement

Share to Liquid Biopsy

Share to Plasma

Source

Identifiers

PMID: 32516802
DOI: 10.1093/clinchem/hvaa103

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Plasma or Serum: Which Is Preferable for Mutation Detection in Liquid Biopsy?PMID 32516802Read ↗

Identification of circulating tumour DNA (ctDNA) from the liquid biopsy results: Findings from an observational cohort studySemantic proximity Read ↗

Clinical relevance of blood-based ctDNA analysis: mutation detection and beyondSemantic proximity Read ↗

The feasibility of using mutation detection in ctDNA to assess tumor dynamics.Semantic proximity Read ↗

Extending Circulating Tumor DNA Analysis to Ultralow Abundance Mutations: Techniques and Challenges.Semantic proximity Read ↗

A clinician's handbook for using ctDNA throughout the patient journey.Semantic proximity Read ↗

Circulating Tumor DNA as a Liquid Biopsy for CancerSemantic proximity Read ↗

ctDNA as a Cancer Biomarker: A Broad OverviewSemantic proximity Read ↗

ctDNA as a cancer biomarker: A broad overview.Semantic proximity Read ↗

Circulating Cell-Free DNA—Diagnostic and Prognostic Applications in Personalized Cancer TherapySemantic proximity Read ↗

Mutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment.Semantic proximity Read ↗

Genomics and Epigenomics Approaches for the Quantification of Circulating Tumor DNA in Liquid Biopsy: Relevance of a Multimodal StrategySemantic proximity Read ↗

Patient monitoring through liquid biopsies using circulating tumor DNASemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.